Faculty, Staff and Student Publications
Publication Date
10-1-2022
Journal
Antibody Therapeutics
Abstract
Diseases in the central nervous system (CNS) are often difficult to treat. Antibody- and protein-based therapeutics hold huge promises in CNS disease treatment. However, proteins are restricted from entering the CNS by the blood-brain barrier (BBB). To achieve enhanced BBB crossing, antibody-based carriers have been developed by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis. In this report, we first provided an overall review on key CNS diseases and the most promising antibody- or protein-based therapeutics approved or in clinical trials. We then reviewed the platforms that are being explored to increase the macromolecule brain entry to combat CNS diseases. Finally, we have analyzed the lessons learned from past experiences and have provided a perspective on the future engineering of novel delivery vehicles for antibody- and protein-based therapies for CNS diseases.
Keywords
Antibody, BBB, Bispecific, TfR, InsR
DOI
10.1093/abt/tbac028
PMID
36540309
PMCID
PMC9759110
PubMedCentral® Posted Date
11-9-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes